The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial.  The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with recurrent high-grade glioma.   Siren believes this marks the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!